# Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures

> **NCT05288283** · PHASE3 · TERMINATED · sponsor: **Jazz Pharmaceuticals** · enrollment: 3 (actual)

## Conditions studied

- Seizures Associated With EMAS

## Interventions

- **DRUG:** GWP42003-P
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05288283
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-31
- **Primary completion:** 2023-09-28
- **Final completion:** 2023-09-28
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The study was terminated due to a business decision.
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05288283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05288283, "Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05288283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*